Covidien Aims To Breathe Life Into Respiratory Biz With Ventilation Pipeline
This article was originally published in The Gray Sheet
Executive Summary
Covidien plans to reinvigorate its respiratory business by targeting higher-growth market segments, such as devices to combat ventilator-associated pneumonia, the company said during its Sept. 10 investor day in New York
You may also be interested in...
Covidien endotracheal tube helps prevent pneumonia
Covidien says its Mallinckrodt SealGuard Evac entdotracheal tube, launched Feb. 2 at the Society of Critical Care Medicine Congress in Nashville, is designed to reduce microaspiration of secretions into the lungs by 95% compared with products currently on the market with high-volume, low-pressure cuffs. The device also helps provide secretion drainage through an integrated suction lumen. Last fall, the company announced plans to target high-growth market segments in the respiratory care business, including devices to fight ventilator-associated pneumonia (1"The Gray Sheet" Sept. 15, 2008, p. 13). The product received 510(k) clearance on Oct. 2, 2008
Covidien endotracheal tube helps prevent pneumonia
Covidien says its Mallinckrodt SealGuard Evac entdotracheal tube, launched Feb. 2 at the Society of Critical Care Medicine Congress in Nashville, is designed to reduce microaspiration of secretions into the lungs by 95% compared with products currently on the market with high-volume, low-pressure cuffs. The device also helps provide secretion drainage through an integrated suction lumen. Last fall, the company announced plans to target high-growth market segments in the respiratory care business, including devices to fight ventilator-associated pneumonia (1"The Gray Sheet" Sept. 15, 2008, p. 13). The product received 510(k) clearance on Oct. 2, 2008
Covidien Device Sales Grow 10% In Q4, But Respiratory Still Faces Headwinds
Covidien's sales of laparoscopic instruments, mesh hernia repair and vessel sealing products helped drive 10% growth in the diversified firm's device business to $1.7 billion in its fiscal fourth quarter, the firm reported Nov. 17